Semaglutide
The most widely studied GLP-1 for long-term weight management.
Prescription only. Requires medical evaluation. Not everyone qualifies.

What it is
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut already releases after eating, which helps regulate appetite signaling and how quickly your stomach empties.
How treatment works
Dosing starts low and titrates upward on a schedule your clinician sets, so your body has time to adjust. Your care team checks in as you move between doses.
Who it's for
- Adults working on sustained weight management
- People who struggle with appetite and portion control
- Patients who prefer a once-weekly injection
How to get started
Four steps, no surprises. Tap any step to see exactly what happens.
Intake
Tell us about your health, goals, and history through a private online questionnaire. About 5 minutes.

Semaglutide is prepared as a compounded medication. Compounded medications are not FDA-approved and are prepared by licensed U.S. compounding pharmacies to meet specific patient needs. They are not reviewed by the FDA for safety, effectiveness, or quality, and are not generic equivalents of brand-name medications. They are prepared pursuant to a valid prescription for an individual patient by our pharmacy partners:
- DiRx, 3540 NW 56th St, STE 204, Ft Lauderdale FL 33309
Also in GLP-1 Weight Management
Dual GIP and GLP-1 action for appetite and metabolic support.
Best for: Adults seeking weight management support
A daily GLP-1 option with a shorter half-life.
Best for: Patients sensitive to weekly dosing
Semaglutide paired with vitamin B12 for energy support.
Best for: Patients starting GLP-1 therapy who want added B12
Dual-pathway therapy with added vitamin B12.
Best for: Patients on dual-pathway therapy who want added B12
See if Semaglutide is right for you
Start your private medical intake. The $75 clinician consultation fee is only charged if a clinician approves you for treatment.
Prescription only. Requires medical evaluation. Not everyone qualifies.